The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?

Cemiplimab is one of seven immune checkpoint inhibitors (ICIs) approved for the first-line (1L) treatment of advanced NSCLC in the US based on EMPOWER-Lung 1 and -Lung 3 trials. In addition to exclusion of NSCLC patients harboring EGFR mutations and ALK fusion from 1L treatment with ICIs, exclusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazel, Danielle, Ou, Saihong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296535/
https://www.ncbi.nlm.nih.gov/pubmed/37383584
http://dx.doi.org/10.2147/LCTT.S413611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296535/
https://www.ncbi.nlm.nih.gov/pubmed/37383584
http://dx.doi.org/10.2147/LCTT.S413611

Ejemplares similares